Nutex Health earnings release, August 6, 2026
NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2026. Nutex Health is a physician-led, healthcare services and operations company with 27 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing physician network.
Financial highlights for the three months ended June 30, 2026:
• Net income attributable to Nutex Health increased to $65.8 million, or diluted EPS of $9.38, compared to a loss of $17.7 million, or diluted EPS of $(2.95), for the three months ended June 30, 2025.
• EBITDA attributable to Nutex Health was $94.1 million and Adjusted EBITDA attributable to Nutex Health was $90.0 million, compared to $(0.5) million and $71.6 million, respectively, for the three months ended June 30, 2025.
• Total visits at the Hospital Division increased 9.6% year over year to 49,962, while visits at same hospitals, which are hospitals that were opened by December 31, 2024, increased 6.3%.
• Net cash provided by operating activities was $34.2 million for the three months ended June 30, 2026 as compared to $27.3 million for the same period in 2025.
Financial highlights for the six months ended June 30, 2026:
• Net income attributable to Nutex Health increased to $112.6 million, or diluted EPS of $15.87, compared to $3.5 million, or diluted EPS of $0.55, for the six months ended June 30, 2025.
• EBITDA attributable to Nutex Health was $162.5 million and Adjusted EBITDA attributable to Nutex Health was $147.5 million, compared to $51.1 million and $144.4 million, respectively, for the six months ended June 30, 2025.
• Total visits at the Hospital Division increased 6.2% year over year to 99,704, while visits at same hospitals increased 3.4%.
• Net cash provided by operating activities was $109.7 million for the six months ended June 30, 2026 as compared to $78.2 million for the same period in 2025; and as of June 30, 2026, the Company had long-term debt, net of $31.1 million, slightly up from $29.2 million as of December 31, 2025.
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
Total revenue decreased 6.3% to $427.2 million for the six months ended June 30, 2026 compared to $455.8 million for the same period in 2025, while revenue at same hospitals decreased 6.0%. Total revenue decreased 13.6% to $210.8 million for the three months ended June 30, 2026 compared to $244.0 million for the same period in 2025, while revenue at same hospitals, decreased 12.1%. Most of the revenue decrease in 2026 compared to 2025 is due to the positive results from the early stage improvement in the IDR process that were realized in the first half of 2025.
The Company has submitted between 50–60% of its claims through IDR; when an award determination is made, Nutex Health currently prevails in over 85% of those determinations and collects, on average, over 80% of the award amounts.
Total arbitration-related costs decreased for both the three and six months ended June 30, 2026, reflected as a $52.3 million reduction to contract services expense. The reduction was driven primarily by the favorable June 30, 2026 retroactive amendment to the Company’s agreement with HaloMD and the reduction in the CMS administrative fee. The HaloMD amendment transitioned certain fees to a pay-on-collected basis retroactive to our original contract date of May 1, 2024 and revised service fee terms for federal and state net settlement amounts obtained on or after July 1, 2026. The CMS administrative fee for the federal IDR process was decreased from $115 to $15 per party per dispute effective June 11, 2026. The cumulative impact from these two key changes directly reduced the contract services expenses for the second quarter and six months ended 2026 period by $52.3 million. Based on current expectations, we anticipate the impact of these favorable changes will lead to an approximate 25-30% reduction in our normalized historical contract services expenses prospectively. This impact is based on the current regulatory outlook and the Company's current expectations. Actual contract services expenses incurred in the future may differ significantly. One additional item within the HaloMD agreement is that the Company may perform dispute resolution services in-house or through the engagement of another third-party vendor or service provider with respect to certain future facilities.
Total stock-based compensation for the six months ended June 30, 2026 was a gain of $1.0 million, compared to an expense of $106.4 million for the same period in 2025. Net income attributable to Nutex Health increased 3100% in the first six months of 2026 as compared to the same period in 2025, underscoring strong operating cash generation and execution of its planned growth strategy.¹
“2026 is continuing to be a solid financial year, including total revenue of $427.2 million, net income attributable to Nutex of $112.6 million, diluted EPS of $15.87 per share and $109.7 million of operating cash flow in the first six months of 2026. We also delivered meaningful operating income improvement, with operating income increasing to $203.0 million for the first six months of 2026 from $114.3 million in the same period of 2025, supported by lower total operating costs and expenses of $194.2 million compared to $212.5 million in the prior-year period. Our balance sheet remains strong with a cash balance of $205.2 million and long-term debt of $31.1 million. We believe we are set up well for finishing the year strong as we continue to grow with the expected opening of three new hospital later this year,” stated Jon Bates, Chief Financial Officer of Nutex Health.... (truncated)continue to execute on initiatives designed to strengthen internal processes and initiatives, expand patient access, and drive both patient volumes and inpatient admissions. Our operating performance, revenue cycle management execution, new hospital openings and disciplined expense management all contributed to improved profitability, including net income attributable to Nutex Health of $112.6 million and diluted EPS of $15.87 for the first six months of 2026," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company’s financial results for the three and six months ended June 30, 2026, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.
Conference Call on Second Quarter 2026 Results
The Company will host a conference call on Friday, August 7, 2026 at 9:30 a.m. CT to discuss its results for the first two quarters of 2026.
Participant Listening: 1-877-407-9208 or 1-201-493-6784
Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6
To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website.²
Financial statements
Income Statement
Three Months Ended June 30, — CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except per share amounts)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Hospital division | 201,852 | 236,302 | 409,422 | 440,249 | |
| Population health management division | 8,900 | 7,683 | 17,815 | 15,525 | |
| Total revenue | 210,752 | 243,985 | 427,237 | 455,774 | |
| Operating costs and expenses: | Payroll | 42,751 | 36,284 | 84,190 | 71,144 |
| Operating costs and expenses: | Contract services | 1,082 | 61,109 | 61,614 | 99,764 |
| Operating costs and expenses: | Medical supplies | 5,342 | 4,812 | 9,351 | 8,613 |
| Operating costs and expenses: | Depreciation and amortization | 5,317 | 5,248 | 10,809 | 10,340 |
| Operating costs and expenses: | Other | 14,981 | 11,608 | 28,264 | 22,651 |
| Operating costs and expenses: | Total operating costs and expenses | 69,473 | 119,061 | 194,228 | 212,512 |
| Operating costs and expenses: | Gross profit | 141,279 | 124,924 | 233,009 | 243,262 |
| Corporate and other costs: | Stock-based compensation | 2,884 | 78,747 | -1,031 | 106,389 |
| Corporate and other costs: | General and administrative expenses | 16,677 | 12,498 | 31,057 | 22,533 |
| Corporate and other costs: | Total corporate and other costs | 19,561 | 91,245 | 30,026 | 128,922 |
| Corporate and other costs: | Operating income | 121,718 | 33,679 | 202,983 | 114,340 |
| Corporate and other costs: | Interest expense, net | 4,671 | 5,678 | 9,353 | 11,798 |
| Corporate and other costs: | Other expense | -38 | 4,269 | -15 | 7,594 |
| Corporate and other costs: | Income before taxes | 117,085 | 23,732 | 193,645 | 94,948 |
| Corporate and other costs: | Income tax expense | 20,768 | 7,588 | 34,565 | 27,998 |
| Corporate and other costs: | Net income | 96,317 | 16,144 | 159,080 | 66,950 |
| Corporate and other costs: | Less: net income attributable to noncontrolling interests | 30,475 | 33,841 | 46,431 | 63,430 |
| Corporate and other costs: | Net income attributable to Nutex Health Inc. | 65,842 | -17,697 | 112,649 | 3,520 |
| Earnings per common share: | Basic | 9.58 | -2.95 | 16.26 | 0.6 |
| Earnings per common share: | Diluted | 9.38 | -2.95 | 15.87 | 0.55 |
Income Statement
Three Months Ended June 30, (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Net income attributable to Nutex Health Inc. | 65,842 | -17,697 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Depreciation and amortization | 5,317 | 5,248 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Interest expense, net | 4,671 | 5,678 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Income tax expense | 20,768 | 7,588 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Allocation to noncontrolling interests | -2,452 | -1,275 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | EBITDA | 94,146 | -458 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Stock-based compensation | 2,884 | 78,747 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Finance lease payments | -7,045 | -6,675 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Adjusted EBITDA | 89,985 | 71,614 |
Income Statement
Six Months Ended June 30, (in thousands)
| Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Net income attributable to Nutex Health Inc. | 112,649 | 3,520 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Depreciation and amortization | 10,809 | 10,340 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Interest expense, net | 9,353 | 11,798 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Income tax expense | 34,565 | 27,998 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Allocation to noncontrolling interests | -4,925 | -2,572 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | EBITDA | 162,451 | 51,084 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Stock-based compensation | -1,031 | 106,389 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Finance lease payments | -13,871 | -13,038 |
| Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA: | Adjusted EBITDA | 147,549 | 144,435 |
Balance Sheet
June 30, 2026 — CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Cash and cash equivalents | 205,208 | 185,574 | |
| Restricted cash | 1,900 | 297 | |
| Accounts receivable | 351,675 | 319,440 | |
| Accounts receivable - related parties | 5,025 | 5,978 | |
| Inventories | 4,207 | 2,866 | |
| Prepaid expenses and other current assets | 17,635 | 24,656 | |
| Total current assets | 585,650 | 538,811 | |
| Property and equipment, net (accumulated depreciation of 35,317 and 31,696 as of June 30, 2026 and December 31, 2025, respectively) | 95,702 | 94,581 | |
| Operating lease right-of-use assets | 26,150 | 26,955 | |
| Financing lease right-of-use assets | 219,067 | 222,367 | |
| Intangible assets, net | 20,580 | 21,230 | |
| Goodwill, net | 13,919 | 13,919 | |
| Other assets | 3,561 | 662 | |
| Total assets | 964,629 | 918,525 | |
| Current liabilities: | Accounts payable | 4,281 | 45,863 |
| Current liabilities: | Accounts payable - related parties | 5,679 | 3,104 |
| Current liabilities: | Lines of credit | 98 | 740 |
| Current liabilities: | Current portion of long-term debt | 8,496 | 13,336 |
Cash Flow
Six Months Ended June 30, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)
| Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Net income | 159,080 | 66,950 | |
| Adjustment to reconcile net income to net cash from operating activities: | Depreciation and amortization | 10,809 | 10,340 |
| Adjustment to reconcile net income to net cash from operating activities: | Stock-based compensation expense | -1,031 | 106,389 |
| Adjustment to reconcile net income to net cash from operating activities: | Changes to deferred taxes | 1,775 | -4,865 |
| Adjustment to reconcile net income to net cash from operating activities: | Debt accretion expense | 44 | 504 |
| Adjustment to reconcile net income to net cash from operating activities: | Non-cash effect of change in estimate | -52,319 | |
| Changes in operating assets and liabilities: | (Increase)/Decrease in Accounts receivable | -32,235 | -116,768 |
| Changes in operating assets and liabilities: | (Increase)/Decrease in Accounts receivable - related party | 953 | -2,135 |
| Changes in operating assets and liabilities: | (Increase)/Decrease in Inventories | -1,341 | 575 |
| Changes in operating assets and liabilities: | (Increase)/Decrease in Prepaid expenses and other current assets | 4,122 | -8,640 |
| Changes in operating assets and liabilities: | (Increase)/Decrease in Operating right-of-use assets | 805 | 121 |
| Changes in operating assets and liabilities: | Increase/(Decrease) in Accounts payable | -4,067 | 19,334 |
| Changes in operating assets and liabilities: | Increase/(Decrease) in Accounts payable - related party | 2,575 | 1,169 |
| Changes in operating assets and liabilities: | Increase/(Decrease) in Operating lease liabilities | -728 | 194 |
| Changes in operating assets and liabilities: | Increase/(Decrease) in Accrued arbitration expenses | 14,729 | 21,043 |
| Changes in operating assets and liabilities: | Increase/(Decrease) in Accrued income tax expense | 3,139 | -18,169 |
| Changes in operating assets and liabilities: | Increase/(Decrease) in Accrued expenses and other current liabilities | 3,408 | 2,180 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 109,718 | 78,222 |
| Cash flows from investing activities: | Acquisitions of property and equipment | -3,741 | -815 |
| Cash flows from investing activities: | Proceeds from restricted short-term investment | 2,941 | |
| Cash flows from investing activities: | Cash related to asset acquisition | -1,994 | |
| Cash flows from investing activities: | Net cash provided by (used in) investing activities | -3,741 | 132 |
Cash Flow
Six Months Ended June 30, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)
| Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | |
|---|---|---|
| Proceeds from lines of credit | 4,606 | |
| Proceeds from notes payable | 258 | |
| Repayments of lines of credit | -642 | -301 |
| Repayments of notes payable | -2,953 | -5,697 |
| Repayments of finance leases | -3,317 | -2,593 |
| Proceeds from exercise of warrants | 75 | |
| Cash related to stock repurchases and retirements | -50,688 | |
| Members' contributions | 1,405 | 242 |
| Members' distributions | -28,620 | -18,776 |
| Net cash used in financing activities | -84,740 | -22,261 |
| Net change in cash, cash equivalents, and restricted cash | 21,237 | 56,093 |
| Cash and cash equivalents - beginning of the period | 185,574 | 40,640 |
| Restricted cash - beginning of period | 297 | |
| Cash and cash equivalents and restricted cash - beginning of period | 185,871 | 40,640 |
| Cash and cash equivalents - end of period | 205,208 | 96,733 |
| Restricted cash - end of period | 1,900 | |
| Cash and cash equivalents and restricted cash - end of period | 207,108 | 96,733 |